ABIVAX (ABVX) Q2 2025 earnings summary

Executive summary

• Report covers the six months ended June 30, 2025, with interim statements approved on September 4, 2025, and limited review by auditors confirming compliance with IAS 34 and no significant anomalies found.

• The company remains focused on late-stage clinical development of obefazimod for ulcerative colitis and Crohn’s disease, with significant R&D investment and ongoing expansion of its commercial organization.

• Major positive phase 3 results for obefazimod in ulcerative colitis were announced post-period, leading to a substantial share price increase and improved outlook for regulatory approval.

• Key business updates include a successful public offering and new share issuances following the exercise of warrants.

Financial highlights

• Net loss for the six months ended June 30, 2025, was €100.8 million, compared to €81.6 million for the same period in 2024.

• Revenue for the period was €2.1 million, mainly from research tax credits and grants.

• R&D expenses rose to €77.9 million (from €64.7 million year-over-year), driven by clinical trial progress and higher personnel expenses.

• Cash and cash equivalents at June 30, 2025, were €60.9 million, down from €144.2 million at December 31, 2024.

• Net financial loss of €7.1 million was driven by interest expenses, non-cash royalty certificate expense, and FX losses, partially offset by interest income.

Outlook and guidance

• Following a €637.5 million ($747.5 million) public offering in July 2025 and recent debt conversions, management expects funding to cover operations through Q4 2027, including 12 months post-expected NDA submission for obefazimod.

• The company anticipates continued losses until significant product revenue is generated.